Online citations, reference lists, and bibliographies.
← Back to Search

Challenges And Opportunities In Drug And Biomarker Development For Nonalcoholic Steatohepatitis: Findings And Recommendations From An American Association For The Study Of Liver Diseases–U.S. Food And Drug Administration Joint Workshop

A. Sanyal, S. Friedman, A. Mccullough, Lara Dimick‐Santos
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)‐approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early‐stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. (Hepatology 2015;61:1392–1405)
This paper references
10.1016/j.pcd.2010.02.004
Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?
M. Ahmed (2010)
10.1002/hep.24491
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study
N. Bhala (2011)
10.1053/J.GASTRO.2005.03.084
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
V. Ratziu (2005)
10.1053/j.gastro.2008.08.050
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
Heather M. Patton (2008)
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. HEPATOLOGY 2003;37:12861292
P Mofrad (2003)
Portal venous pressure measurement and its clinical significance.
Atterbury Ce (1983)
10.1097/MPG.0b013e318192d224
Trends in Nonalcoholic Fatty Liver Disease–related Hospitalizations in US Children, Adolescents, and Young Adults
C. Koebnick (2009)
10.1016/j.jhep.2009.03.025
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.
S. Zhang (2009)
10.1185/03007995.2010.506375
Population-based risk factors and resource utilization for HCC: US perspective
A. Sanyal (2010)
Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis: results from the PIVENS Trial. Gastroenterology 2013;144:S951
R Vuppulanchi (2013)
10.1016/j.jhep.2009.01.014
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis.
C. Ripoll (2009)
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:1904-1912
K David (1912)
10.1002/hep.23849
Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function
A. Milona (2010)
10.1002/hep.22868
Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network
K. David (2009)
10.1002/hep.23527
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Mustafa S Ascha (2010)
10.1016/J.JHEP.2005.10.013
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
G. D'Amico (2006)
10.1002/HEP.1840110114
The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years
Elizabeth E. Powell (1990)
10.1002/hep.20466
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
J. D. Browning (2004)
10.1007/S11894-008-0011-1
The obesity epidemic and nonalcoholic fatty liver disease in children
W. Dunn (2008)
10.1053/JHEP.2003.50229
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
Pouneh S. Mofrad (2003)
10.1097/01.mpg.0000239995.58388.56
Pediatric Nonalcoholic Fatty Liver Disease: A Critical Appraisal of Current Data and Implications for Future Research
H. Patton (2006)
10.1111/j.1365-2036.2009.04181.x
Symptoms and quality of life in obese children and adolescents with non‐alcoholic fatty liver disease
K. D. Kistler (2010)
10.1038/nrgastro.2010.21
Pathology of nonalcoholic fatty liver disease
E. Brunt (2010)
10.1016/J.TRANSPROCEED.2004.03.095
Liver transplant recipients mortality on the waiting list: long-term comparison to Child-Pugh classification and MELD.
I. Boin (2004)
Longterm follow-up of patients with nonalcoholic fatty liver
N Rafiq (2009)
10.1111/j.1478-3231.2011.02753.x
The Framingham risk score and heart disease in nonalcoholic fatty liver disease
S. Treeprasertsuk (2012)
Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010;4:129-137
MH Ahmed (2010)
10.1056/NEJMoa0907929
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
A. Sanyal (2010)
10.1111/j.1365-2893.2010.01371.x
Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV‐coinfected patients
M. Sánchez-Conde (2011)
10.1002/hep.20842
Histopathology of pediatric nonalcoholic fatty liver disease
J. Schwimmer (2005)
10.1016/j.cgh.2008.11.005
Long-term follow-up of patients with nonalcoholic fatty liver.
N. Rafiq (2009)
Hepatic venous pressure gradient predicts clinical HEPATOLOGY
C Ripoll
Serum keratin fgragment 18 ( CK 18 ) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease : results from teh TONIC trial
AK Jain (2013)
10.1016/S0016-5085(99)70506-8
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
C. Matteoni (1999)
10.1053/GAST.2001.21193
Factors associated with poor health-related quality of life of patients with cirrhosis.
G. Marchesini (2001)
10.1053/J.GASTRO.2005.04.014
The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
L. Adams (2005)
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
J. Ludwig (1980)
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292
P Mofrad (2003)
10.1111/j.1572-0241.2001.03956.x
Health-related quality of life in chronic liver disease: the impact of type and severity of disease
Z. Younossi (2001)
10.1002/hep.23315
Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long‐term treatment against cirrhosis trial
J. Everhart (2010)
10.1016/J.JHEP.2004.09.012
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
L. Adams (2005)
10.1002/hep.20062
The hepatic venous pressure gradient: Anything worth doing should be done right
R. Groszmann (2004)
10.1111/jgh.12156
Predictive value of Refit Model for End‐Stage Liver Disease, Refit Model for End‐Stage Liver Disease‐Na, and pre‐existing scoring system for 3‐month mortality in Korean patients with cirrhosis
Ja Kyung Koo (2013)
10.1194/jlr.M004929
Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via Gαi-protein-coupled receptors and the AKT pathway[S]
Risheng Cao (2010)
10.1038/nrgastro.2013.41
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Q. Anstee (2013)
10.1038/ajg.2010.152
Association Between Metabolic Syndrome and Liver Histology Among Children With Nonalcoholic Fatty Liver Disease
H. Patton (2010)
Progression to bridging fibrosis in nonalcoholic fatty liver disease over 4 years in the NASH CRN. HEPATOLOGY 2013;58:495A
EM Brunt (2013)
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association
N Chalasani (2012)
10.1055/s-2008-1040325
Assessment of prognosis of cirrhosis.
F. Durand (2008)
progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the Nash Crn : 602
E. Brunt (2013)
10.3164/jcbn.09-71
Bile Acids Induce Cdx2 Expression Through the Farnesoid X Receptor in Gastric Epithelial Cells
Y. Xu (2010)
Predictive value of refit MELD, refit MELD-Na and pre-existing scoring system for 3 month mortality in Korean patients with cirrhosis
JK Koo (2013)
10.3748/WJG.15.2097
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation.
B. Renga (2009)
10.1021/jm101336m
Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.
Valentina Sepe (2011)
10.1093/carcin/bgq050
Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.
Darcey L H Smith (2010)
10.1053/j.ajkd.2013.11.027
Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients.
E. Peters (2014)
10.1053/j.gastro.2012.04.001
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
N. Chalasani (2012)
10.1038/ajg.2010.18
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study
L. Adams (2010)
Histological predictors of improvement of NASH: results from NASH Clinical Research Network PIVENS trial
E Brunt (2012)
Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis : Results From the Pivens Trial
R Vuppulanchi (2013)
10.1002/hep.26156
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
D. Kim (2013)
Portal venous pressure measurement and its clinical significance.
C. E. Atterbury (1983)
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873
M Ekstedt (2006)
10.1002/HEP.1840070124
Compensated cirrhosis: Natural history and prognostic factors
P. Ginès (1987)
10.1002/hep.24268
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality
Z. Younossi (2011)
10.1016/j.bmcl.2009.04.047
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Jonathan Y. Bass (2009)
Histological predictors of improvement of NASH: results from NASH Clinical Research Network PIVENS trial. Hepatology 2012;October:A xxx
E Brunt (2012)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis
AJ Sanyal (2006)
10.1038/nrgastro.2013.183
NAFLD, NASH and liver cancer
G. Michelotti (2013)
10.1002/hep.20871
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era
C. Ripoll (2005)
10.2174/092986710790112666
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.
S. Fiorucci (2010)
10.1111/j.1572-0241.2002.05922.x
Subacute liver failure in obese women
S. Caldwell (2002)
10.1053/GAST.2003.50016
Model for end-stage liver disease (MELD) and allocation of donor livers.
R. Wiesner (2003)
10.1002/hep.21103
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C
A. Sanyal (2006)
10.1038/ajg.2011.157
The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers
J. Bajaj (2011)
10.1016/j.jpeds.2009.06.014
Pediatric nonalcoholic fatty liver disease in 2009.
A. Alisi (2009)
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research
K David (1912)
10.1053/j.gastro.2013.06.057
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
P. Angulo (2013)
10.1007/s10620-013-2743-5
Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
M. Stepanova (2013)
10.1111/j.1365-2036.2010.04484.x
Comparison of balloon vs. straight catheter for the measurement of portal hypertension
A. Zipprich (2010)
10.1002/hep.21327
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes
M. Ekstedt (2006)
10.1111/j.1572-0241.1999.01377.x
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
E. Brunt (1999)
10.1007/s11894-012-0301-5
Quality of Life in Cirrhosis
Anthony Loria (2012)
10.1002/hep.20701
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
D. Kleiner (2005)
10.1016/S0016-5085(13)63534-9
518 Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis: Results From the Pivens Trial
R. Vuppalanchi (2013)
10.5772/53463
Pediatric Nonalcoholic Fatty Liver Disease
Ebe D'Adamo (2013)
10.1016/j.ab.2009.11.008
Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.
Ki-Cheol Han (2010)
10.1053/J.GASTRO.2007.10.024
Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.
S. Baumeister (2008)
10.1111/j.1572-0241.2008.02034.x
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
W. Dunn (2008)
10.1111/j.1478-3231.2012.02830.x
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis
A. Zipprich (2012)
10.1097/01.psy.0000221276.17823.df
Depression, Anxiety, and Nonalcoholic Steatohepatitis
Jill E Elwing (2006)
10.1177/0884533613489153
Pediatric nonalcoholic fatty liver disease.
Molly A Bozic (2013)
10.1002/lt.20265
When is a patient too well and when is a patient too sick for a liver transplant?
R. Merion (2004)
10.1053/JHEP.2001.22172
A model to predict survival in patients with end‐stage liver disease
P. Kamath (2001)
10.1002/hep.23784
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
B. Neuschwander-Tetri (2010)
10.1038/nrgastro.2013.171
The global NAFLD epidemic
R. Loomba (2013)
10.1053/J.GASTRO.2007.05.024
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
C. Ripoll (2007)
10.7326/0003-4819-61-6-1206_2
The liver and portal hypertension
C. Child (1964)
10.1111/j.1365-2036.2007.03426.x
Health‐related quality of life in patients with non‐alcoholic fatty liver disease
A. Dan (2007)
Surgery and portal hypertension.
Child Cg (1964)
Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis : results from the PIV - ENS Trial
R Vuppulanchi (2013)
10.1038/ajg.2014.264
Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization
Kavish R. Patidar (2014)



This paper is referenced by
10.3748/wjg.v24.i30.3361
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
S. Leoni (2018)
10.1016/j.vascn.2019.106651
Variation in diagnostic NAFLD/NASH read-outs in paired liver samples from rodent models.
V. S. Jensen (2019)
10.1056/NEJMra1503519
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
A. M. Diehl (2017)
10.1097/MOG.0000000000000356
Current and future pharmacologic treatment of nonalcoholic steatohepatitis
B. Banini (2017)
10.1194/jlr.M093799
FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice
Timothy D Rohrbach (2019)
10.1016/j.lfs.2017.03.012
Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling
N. Duan (2017)
10.1016/S1957-2557(17)30167-0
Les futurs traitements de la NASH
L. Serfaty (2017)
10.1146/annurev-pharmtox-010617-052545
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
J. Wattacheril (2018)
Improved liver T1rho measurement precision with a breathhold black blood single shot fast spin echo acquisition: a validation study in healthy volunteers
Yi-Xiang J. Wang (2016)
10.2147/HMER.S265473
Identifying High-Risk NASH Patients: What We Know so Far
M. Schulz (2020)
10.1001/jamanetworkopen.2019.12565
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
D. Kleiner (2019)
10.21037/TGH.2020.01.04
Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry
Amon Asgharpour (2020)
10.1016/j.cct.2018.04.002
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
T. Kessoku (2018)
10.1002/hep.29607
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
M. Siddiqui (2018)
10.1016/j.clinre.2020.03.021
Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis.
Xiaoyu Xie (2020)
10.1016/j.cgh.2015.07.029
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
A. Ahmed (2015)
10.1007/s00535-018-01542-w
Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
Gurmehr Brar (2018)
10.1016/j.jhepr.2020.100099
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
Lorraine McSweeney (2020)
10.1002/hep.28031
The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique
G. Silva-Junior (2015)
10.1002/hep.28672
Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy
M. Armstrong (2016)
10.1002/hep.29724
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Z. Younossi (2018)
10.1016/j.jcmgh.2020.06.001
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Trenton T. Ross (2020)
10.1053/j.gastro.2017.06.016
How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
H. Tilg (2017)
10.1016/S2468-1253(17)30365-5
The painful reality of end-stage liver disease in NASH.
Vlad Ratziu (2018)
10.1038/ctg.2016.28
Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter
A. Arslanow (2016)
10.1177/1756283X15621232
Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial
S. Lin (2016)
10.1055/s-0037-1618587
Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
V. Ajmera (2018)
10.1016/j.cct.2016.02.012
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
S. Friedman (2016)
10.1186/s12916-017-0806-8
Non-alcoholic fatty liver disease
B. Neuschwander-Tetri (2017)
10.1016/J.CGH.2017.12.023
The Clinical Relevance of Differentiating Nonalcoholic Steatohepatitis From Simple Steatosis Reply
Pauline L M Verhaegh (2018)
Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
William N. Hannah (2016)
10.1038/s41575-019-0144-8
Past, present and future perspectives in nonalcoholic fatty liver disease
A. Sanyal (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar